Results 241 to 250 of about 260,498 (362)

Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation

AIDS (London), 2003
M. Caron, M. Auclair, H. Sterlingot, M. Kornprobst, J. Capeau   +4 more
semanticscholar   +1 more source

Exploiting Pharmacokinetic/Pharmacodynamic Methods for Optimizing and Accelerating Drug Development of Innovative Anti‐Infectives

ChemMedChem, Volume 21, Issue 2, January 2026.
This article focuses on the interplay of absorbed, distributed, metabolized, and excreted (ADME) properties; in vivo pharmacokinetics (PK); and pharmacodynamics (PD) supported by in silico PK/PD modeling techniques to improve drug development by acceleration of processes and reducing attrition risks.
Katharina Rox
wiley   +1 more source

Inhibitor-complexed structures of an HIV-1 protease mutant displaying cross resistance to all clinical trial candidates [PDF]

, 1996
Yong‐Bin Yan, Y. Li, Hilary B. Schock, Z. Chen   +3 more
openalex   +1 more source

The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults

AIDS (London), 2004
Mustafa A. Noor, R. Parker, E. O'Mara, D. Grasela, A. Currie, S. Hodder, F. Fiedorek, D. Haas   +7 more
semanticscholar   +1 more source

Pyroptosis in Peripheral Neuropathy: From Molecular Mechanisms to Therapeutic Targeting

CNS Neuroscience &Therapeutics, Volume 32, Issue 1, January 2026.
Pyroptosis is a key inflammatory cell death pathway in peripheral neuropathy, with opposing roles: it perpetuates neuropathic pain but can be induced to kill neuroblastoma cells. This review consolidates mechanistic understanding and therapeutic strategies, arguing for a shift from disease‐centric to target‐centric treatment approaches to improve ...
Jinhuan Wei, Mingyue Liuyuan, Zhixin Ye, Xueying Wang, Xueli Zhou, Yifan Shan, Cheng He, Chunting Zhu, Chicheng Zhou, Jingyin Bao, Yonghui Zhang, Gang Chen   +11 more
wiley   +1 more source

A Phase 1 Dose‐Escalation, Food Effect, and Drug–Drug Interaction Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MALT1 Inhibitor, SGR‐1505, in Healthy Volunteers

Clinical Pharmacology in Drug Development, Volume 15, Issue 1, January 2026.
Abstract SGR‐1505 is a novel small‐molecule inhibitor of MALT1, a key mediator of NF‐κB signaling implicated in the pathogenesis of B‐cell malignancies. This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of SGR‐1505 in healthy volunteers. In this four‐part, open‐label study, 73 participants received single or multiple
Vipul K. Gupta, Brian Yoo, Daniel Weiss, Frank G. Basile, Edgar Schuck, Christopher M. Rubino, Sen Zhang, Stephen E. Maxwell, Wenxin Zheng, Joanne B. L. Tan, David Stenehjem, Paul B. Watkins, Margaret Dugan, Wu Yin, D. Hamish Wright, Karen Akinsanya, Jason Lickliter   +16 more
wiley   +1 more source

Second protease inhibitor approved for HIV therapy [PDF]

, 1996

openalex   +1 more source

RNF39 promotes colorectal cancer progression by driving RINT1 degradation and suppressing ER stress‐induced apoptosis

Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.
RNF39, an E3 ubiquitin ligase upregulated by MEF2D in COAD, promotes RINT1 degradation, affecting UPR and ER stress. Loss of RNF39 leads to RINT1 accumulation, enhancing CHOP expression and sensitizing cells to apoptosis. Abstract Background Colorectal adenocarcinoma (COAD) cells exploit stress‐adaptation programs, such as the unfolded protein response
Lu Chen, Chunluan Yuan, Teng Yu, Kaiyuan Hui, Xiuming Li, Xiaozhu Shen, Xiaodong Jiang, Bin Liu   +7 more
wiley   +1 more source

HAART and lungs: do HIV protease inhibitors impact cancer risk? [PDF]

AIDS, 2015
Uldrick TS.
europepmc   +1 more source

HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy

AIDS (London), 1998
C. Craig, E. Race, J. Sheldon, L. Whittaker, Susan M. Gilbert, Alec R. Moffatt, J. Rose, S. Dissanayeke, G. Chirn, I. Duncan, N. Cammack   +10 more
semanticscholar   +1 more source